Could a 5-Day pill shield frail seniors from COVID's worst outcomes?
NCT ID NCT07089680
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This study looks at whether the antiviral medication Paxlovid can reduce the risk of severe illness, death, and loss of daily functioning in older adults living in long-term care hospitals in Korea. Researchers will compare health outcomes of residents aged 60 and older who received Paxlovid for COVID-19 with those who did not, using medical records. The goal is to see if this treatment helps maintain independence and cognitive function in a vulnerable population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nirmatrelvir and ritonavir (Paxlovid), an oral antiviral medication
- What this could lead to
- If effective, Paxlovid could help protect vulnerable older adults in long-term care from severe COVID-19, death, and loss of independence.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. The medication's benefits in this frail population are not yet confirmed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONAVIRUS DISEASE 2019 (COVID-19) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gangnam-gu Haengbok Convalescence Hospital
Gangnam-gu, South Korea
-
Incheon Eun-Hye Convalescent Hospital
Seogu, South Korea
-
Jeonnam Jeil Hospital
Hwasun-gun, South Korea
-
Seocho-Cham Nursing Hospital
Seocho-gu, South Korea
-
Songdo Hyoja Hospital
Yeonsu-gu, South Korea
-
The Good Light Hospital
Gwangju, 12748, South Korea
-
bobath Memorial Hospital
Gyeonggi-do, 13552, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.